Related to FDA Details Requirements for Regulatory Submissions of Genomic Biomarkers

• Proteome Sciences Inks Deal with Axela to Develop Brain-Damage Biomarker Assays
  
• FDA Orders Partial Clinical Hold on Genmab’s Anticancer Agent
  
• NextGen Includes Thermo Fisher’s Mass Spec Technology to Its Suite of Biomarker Services
  
• FDA Requires More Data to Approve ViroPharma’s Drug for Acute Treatment of Angioedema
  
• Axis-Shield Acquires Rights to Develop Sepsis Diagnostic from Hansa Medical
  
• Scientists Uncover Tumor Suppressor in Colorectal Cancer
  
• Novartis Gets FDA Okay for Drug to Treat Rare Inflammatory Disorder
  
• Appendicitis Marker Identified in Children
  
• Swiss Viollier to Launch Colorectal Cancer Blood Test in Europe
  
• DiaGenic to Help Merz with Patient Stratification in Alzheimer’s Trials
  
• Researchers Find Prognostic Marker for Breast Cancer in Stroma
  
• Celera Licenses Five Cancer-Related Targets to Bayer Schering Pharma
  
• FDA Asks Spectrum Pharmaceuticals for Past Clinical Study Data to Help Expand Approval of NHL Drug
  
• Protalix’ Phase III Candidate for Gaucher’s May Fill the Treatment Gap due to Genzyme’s Plant Closure
  
• Shire’s Gaucher Disease Drug Candidate Being Considered by FDA
  
• FDA Gives Osmetech’s Cystic Fibrosis Genotyping Test a Thumbs Up
  
• Cepheid Gains FDA Approval for C. Difficile Molecular Diagnostic
  
• FDA Says Erbitux No Good for Those with Certain K-ras Mutations
  
• FDA Clears Novartis Medication as Initial Therapy for Blood Pressure
  
• Lohocla to Use Biosystems International’s Platform for Alcoholic Liver Disease Biomarker Discovery